Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Colon Cancer Adjuvant Trials Need 3-Year Disease-Free Survival – FDA Cmte

May 17 2004

• By The Pink Sheet

Related Content

FDA Support For Survival Endpoints Affirmed At Colon Cancer Workshop

Nov 17 2003

Progression-Free Survival Is Good Endpoint For Metastatic NSCLC, Cmte. Says

Dec 22 2003

Progression-Free Survival Is Adequate Primary Endpoint For Melanoma Trials

May 17 2004

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window